ReviewFrontiers in microbiology2014
Antivirulence activity of azithromycin in Pseudomonas aeruginosa.
Review in Frontiers in microbiology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 61 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
61 citing papers in PubMed, 136 citations in OpenAlex.
- Beyond lethal doses: sub-MIC levels of multi-class antibiotics induce species- and isolate-dependent biofilm inhibition in gram-negative pathogens.BMC microbiology · 2026Article
- Effects of quercetin, baicalein, azithromycin, and their combination on biofilm formation, virulence factors and gene expression associated with Pseudomonas aeruginosa quorum sensing.Molecular biology reports · 2026Article
- Organosulfur scaffolds as quorum sensing and biofilm modulators in Gram-negative bacteria.FEMS microbiology reviews · 2026Review
- Menadione as Antibiotic Adjuvant AgainstAntibiotics (Basel, Switzerland) · 2025Article
- Prevalence of azithromycin resistance after the COVID-19 era in clinical bacterial isolates from a tertiary care hospital in Gurugram, India.Frontiers in microbiology · 2025Article
- Gram Negative Biofilms: Structural and Functional Responses to Destruction by Antibiotic-Loaded Mixed Polymeric Micelles.Microorganisms · 2024Article
- Formulation and evaluation of azithromycin-loaded silver nanoparticles for the treatment of infected wounds.International journal of pharmaceutics: X · 2024Article
- Effects of quorum sensing-interfering agents, including macrolides and furanone C-30, and an efflux pump inhibitor on nitrosative stress sensitivity inMicrobiology (Reading, England) · 2024Article
- Spiramycin DisarmsAntibiotics (Basel, Switzerland) · 2023Article
- Anti-Virulence Strategy of Novel Dehydroabietic Acid Derivatives: Design, Synthesis, and Antibacterial Evaluation.International journal of molecular sciences · 2023Article
- Therapeutic Potential of an Azithromycin-Colistin Combination against XDRAntibiotics (Basel, Switzerland) · 2023Article
- New Attempts to Inhibit Methicillin-ResistantInfection and drug resistance · 2023Article
- Immunomodulatory Effects of Macrolides Considering Evidence from Human and Veterinary Medicine.Microorganisms · 2022Review
- Antibiotic resistance in chronic respiratory diseases: from susceptibility testing to the resistome.European respiratory review : an official journal of the European Respiratory Society · 2022Review
- The Xanthophyll Carotenoid Lutein Reduces the Invasive Potential ofInternational journal of molecular sciences · 2022Article
- Targeting the Holy Triangle of Quorum Sensing, Biofilm Formation, and Antibiotic Resistance in Pathogenic Bacteria.Microorganisms · 2022Review
- Recent Advances in Antimicrobial Nano-Drug Delivery Systems.Nanomaterials (Basel, Switzerland) · 2022Review
- Article
- Article
- Repurposing Dimetridazole and Ribavirin to disarmFrontiers in microbiology · 2022Article
1 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antibiotics represent our bulwark to combat bacterial infections, but the spread of antibiotic resistance compromises their clinical efficacy. Alternatives to conventional antibiotics are urgently needed in order to complement the existing antibacterial arsenal. The macrolide antibiotic azithromycin (AZM) provides a paradigmatic example of an "unconventional" antibacterial drug. Besides its growth-inhibiting activity, AZM displays potent anti-inflammatory properties, as well as antivirulence activity on some intrinsically resistant bacteria, such as Pseudomonas aeruginosa. In this bacterium, the antivirulence activity of AZM mainly relies on its ability to interact with the ribosome, resulting in direct and/or indirect repression of specific subsets of genes involved in virulence, quorum sensing, biofilm formation, and intrinsic antibiotic resistance. Both clinical experience and clinical trials have shown the efficacy of AZM in the treatment of chronic pulmonary infections caused by P. aeruginosa. The aim of this review is to combine results from laboratory studies with evidence from clinical trials in order to unify the information on the in vivo mode of action of AZM in P. aeruginosa infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.